Early Clinical PET Imaging Results with the Novel PHF-Tau Radioligand [F18]-T808
Early Clinical PET Imaging Results with the Novel PHF-Tau Radioligand [F18]-T808
复制标题
DOI：
10.3233/jad-130098
复制
发表时间：
2014-01-01
影响因子：
4
通讯作者：
Kolb, Hartmuth C.
中科院分区：
文献类型：
--
作者：
Chien, David T.;Szardenings, A. Katrin;Kolb, Hartmuth C.
过度磷酸化tau蛋白（PHF-tau）的聚集体，如神经元缠结，与阿尔茨海默病的认知障碍程度有关。我们最近报道了一种新型PHF-tau靶向PET显像剂[F18]-T807的早期临床结果。从那时起，我们研究了第二种新型PHF-tau靶向PET成像剂[ F18]-T808，其具有不同的药代动力学特征，这可能有利于阿尔茨海默病和其他tau蛋白病的成像。在这里，我们描述了使用[F18]-T808的第一个人脑图像。
Aggregates of hyperphosphorylated tau (PHF-tau), such as neurofibrillary tangles, are linked to the degree of cognitive impairment in Alzheimer's disease. We have recently reported early clinical results of a novel PHF-tau targeting PET imaging agent, [F18]-T807. Since then, we have investigated a second novel PHF-tau targeting PET imaging agent, [ F18]-T808, with different pharmacokinetic characteristics, which may be favorable for imaging Alzheimer's disease and other tauopathies. Here, we describe the first human brain images with [F18]-T808.